Rebecsinib

Rebecsinib (17S-FD-895) is an experimental anticancer medication derived by modification of the natural product Pladienolide B, which acts as an inhibitor of splicing-mediated activation of the enzyme ADAR1, and is in development as a potential treatment for leukemia.
Wikipedia contributors, "Rebecsinib", Wikipedia, revision 1330459755, retrieved 20 November 2026, source, CC BY-SA 4.0.